Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2003
12/24/2003CA2477878A1 Peptides selectively lethal to malignant and transformed mammalian cells
12/23/2003US6667404 Retroviral protease inhibiting compounds
12/23/2003US6667341 Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters; anticancer agents, hemological disorders, and inherited metabolic disorders
12/23/2003US6667337 Combination therapy for cancer
12/23/2003US6667334 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
12/23/2003US6667320 For therapy of infalmmation; asthma, cancer, arthritis, multiple sclerosis; prophylaxis of infection of target cells by a human immunodeficiency virus (HIV)
12/23/2003US6667316 Pharmaceutically active isoindoline derivatives
12/23/2003US6667313 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
12/23/2003US6667311 Also containing pyrimidine or pyridine rings
12/23/2003US6667304 Affinity for melatonin receptors; sleep disorders; N-(2-(2-methoxy-6H-pyrido(2',3':4,5)pyrrolo(2,1-a)isoindol-11 -yl)ethyl)acetamide; N-(2-(3-methoxy-6,7,8,9-tetrahydropyrido (3,2-b)indolizin-5-yl) ethyl)acetamide
12/23/2003US6667302 Heterocyclic topoisomerase poisons
12/23/2003US6667300 Purinyl substituted quinazoline-4-one derivatives
12/23/2003US6667298 26,27-Homologated-20-EPI-2-alkyl-19-NOR-vitamin D compounds
12/23/2003US6667291 Endometrial Steroid Binding Protein II activity; endometrial and breast cancers
12/23/2003US6667156 Treating nervous system tumors; obtain cells, incubate with modulator, evaluate tumor propagtion
12/23/2003US6667053 D and L etherlipid stereoisomers and liposomes
12/23/2003US6667037 Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
12/23/2003US6667024 Kit comprising molecule with radioisotope binding site linked to antigen-binding fragment of antibody that specifically binds to tumor associated antigen, and metal chelator and basic amino acid or peptide clearing agents
12/23/2003US6666811 Coating microsphere with radioactive, diffusion barrier, and protective layers; solid, multilayered seamless elements are implanted; heating tumors
12/23/2003CA2267800C Tricyclic compounds having activity as ras-fpt inhibitors
12/19/2003WO2002101076A2 Methods for targeted expression of therapeutic nucleic acid
12/19/2003CA2460095A1 Methods for targeted expression of therapeutic nucleic acid
12/18/2003WO2003104807A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003WO2003104473A2 Galactosyl isomalt, method for production and use thereof
12/18/2003WO2003104467A1 Means and methods for the production of adenovirus vectors
12/18/2003WO2003104428A2 Gene differentially expressed in breast and bladder cancer and encoded polypeptides
12/18/2003WO2003104426A2 Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof
12/18/2003WO2003104412A2 Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling
12/18/2003WO2003104260A2 Pharmaceutical formulation
12/18/2003WO2003104254A2 Novel derivatives of androstane and androstene with ascorbic a cid and use thereof in treating or preventing various conditions, diseases, and disorders
12/18/2003WO2003104250A1 New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
12/18/2003WO2003104246A1 Carbacyclic phosphatidic acid derivative
12/18/2003WO2003104238A1 Novel compound having antitumor activity and process for producing the same
12/18/2003WO2003104235A1 Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]pyrazines and decahydropyrazino[1,2-a]azepines
12/18/2003WO2003104230A1 Bicyclic pyrimidine derivatives
12/18/2003WO2003104229A1 Novel fused imidazole derivative
12/18/2003WO2003104226A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
12/18/2003WO2003104225A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
12/18/2003WO2003104224A1 Metabolites of prinomastat and their sythesis
12/18/2003WO2003104223A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003WO2003104222A1 Bisindolyl-maleimid derivatives as kinase inhibitors
12/18/2003WO2003104219A1 Nf-kb inhibitors
12/18/2003WO2003104218A1 Nf-:b inhibitors
12/18/2003WO2003104205A1 Aryloximes
12/18/2003WO2003104204A1 Pyridazine derivatives
12/18/2003WO2003104203A1 Therapeutic molecules and methods-1
12/18/2003WO2003104195A1 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
12/18/2003WO2003104181A2 Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
12/18/2003WO2003104178A1 Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
12/18/2003WO2003103822A2 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
12/18/2003WO2003103772A1 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
12/18/2003WO2003103743A2 Medical device for intra-lumenal delivery of pharmaceutical agents
12/18/2003WO2003103725A1 Compositions and methods for the diagnosis and treatment of tumor
12/18/2003WO2003103715A1 Modified byrodin 1 with reduced immunogenicity
12/18/2003WO2003103714A1 Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same
12/18/2003WO2003103712A1 Combinations comprising epothilones and pharmaceutical uses thereof
12/18/2003WO2003103708A1 BIOFUNCTIONAL CpG OR OLIGO-/POLYNUCLEOTIDE AND TOXIN OR ENTEROTOXIN CONTAINING COMPOSITION
12/18/2003WO2003103706A2 Immunogenic compositions
12/18/2003WO2003103705A1 Metalloproteinase inhibitors
12/18/2003WO2003103702A1 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
12/18/2003WO2003103695A1 Novel therapeutic use of polypodium extracts
12/18/2003WO2003103687A1 Liquid formulation of decitabine and use of the same
12/18/2003WO2003103682A1 Compositions for cancer therapy saponins or sapogenins
12/18/2003WO2003103678A1 Oxaziridine precursors and derivatives in the treatment of epithelial cancer tumors
12/18/2003WO2003103676A2 Method of treating cancer using kinase inhibitors
12/18/2003WO2003103671A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/18/2003WO2003103666A2 Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
12/18/2003WO2003103663A2 Substituted pyrrolines as kinase inhibitors
12/18/2003WO2003103661A1 SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
12/18/2003WO2003103655A1 Therapeutic agent for cancer
12/18/2003WO2003103645A1 Fractionated extraction of natural source carotenoids with a high lycopene content, using supercritical fluids
12/18/2003WO2003103644A2 Guanidino phenylalanin compounds used as urokinase inhibitors
12/18/2003WO2003103631A1 Novel high viscosity embolizing compositions comprising prepolymers
12/18/2003WO2003103588A2 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
12/18/2003WO2003103585A2 Methods of treating angiogenesis, tumor growth, and metastasis
12/18/2003WO2003103584A2 Ether substituted imidazopyridines
12/18/2003WO2003103583A2 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
12/18/2003WO2003103577A2 Novel recombinant anticoagulant proteins
12/18/2003WO2003103575A2 Compounds, compositions, and methods
12/18/2003WO2003103569A2 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
12/18/2003WO2003103478A2 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
12/18/2003WO2003097052A3 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
12/18/2003WO2003087087A3 Heterocyclic compounds and their use as modulators of p38 map kinase
12/18/2003WO2003074500A3 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
12/18/2003WO2003074449A3 Multi-substitued selective androgen receptor modulators and methods of use thereof
12/18/2003WO2003074027A3 Self emulsifying drug delivery systems for poorly soluble drugs
12/18/2003WO2003072606A3 Galectin-8and functional derivatives as binding agents for cd44 glycoproteins and methods of use
12/18/2003WO2003070701B1 Syntheses of quinazolinones
12/18/2003WO2003066638A3 The synthesis of naturally occuring ecteinascidins and related compounds
12/18/2003WO2003066630A3 Quinolinone derivatives for treating cell proliferation related disorders
12/18/2003WO2003057159A3 Psoriasin expression by breast epithelial cells
12/18/2003WO2003051917A3 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/18/2003WO2003051401A3 Stabilised mrna tumour vaccine
12/18/2003WO2003050108A8 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
12/18/2003WO2003050064B1 Mitotic kinesin inhibitors
12/18/2003WO2003045428A3 Use of a technically modified cell as a vaccine for treating tumoral disease
12/18/2003WO2003044021A3 Substituted indolizine-like compounds and methods of use
12/18/2003WO2003039444B1 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
12/18/2003WO2003037164A3 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
12/18/2003WO2003031606A3 Crystal structure of an aurora kinase catalytic domain, and use thereof
1 ... 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 ... 2211